GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » ROE % Adjusted to Book Value

Arovella Therapeutics (FRA:E4NA) ROE % Adjusted to Book Value : -11.29% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics ROE % Adjusted to Book Value?

Arovella Therapeutics's ROE % for the quarter that ended in Jun. 2024 was -133.85%. Arovella Therapeutics's PB Ratio for the quarter that ended in Jun. 2024 was 11.86. Arovella Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -11.29%.


Arovella Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Arovella Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics ROE % Adjusted to Book Value Chart

Arovella Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -131.90 -33.39 -89.48 -19.64 -9.82

Arovella Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.78 -51.11 -35.52 -6.73 -11.29

Competitive Comparison of Arovella Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Arovella Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arovella Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's ROE % Adjusted to Book Value falls into.



Arovella Therapeutics ROE % Adjusted to Book Value Calculation

Arovella Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-116.42% / 11.86
=-9.82%

Arovella Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-133.85% / 11.86
=-11.29%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arovella Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Arovella Therapeutics Business Description

Traded in Other Exchanges
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines